MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -19.71 Million EUR | -42.16% |
| 2022 | -13.87 Million EUR | -51.75% |
| 2021 | -9.14 Million EUR | -70.84% |
| 2020 | -5.35 Million EUR | 19.51% |
| 2019 | -6.64 Million EUR | -46.22% |
| 2018 | -4.54 Million EUR | -17.82% |
| 2017 | -3.85 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.42 Million EUR | -13.95% |
| 2024 Q2 | -6.42 Million EUR | 0.0% |
| 2023 Q1 | -4.21 Million EUR | 33.01% |
| 2023 Q2 | -8.43 Million EUR | -100.0% |
| 2023 FY | -19.71 Million EUR | -42.16% |
| 2023 Q3 | -5.64 Million EUR | 33.12% |
| 2023 Q4 | -5.64 Million EUR | 0.0% |
| 2022 FY | -13.87 Million EUR | -51.75% |
| 2022 Q4 | -6.29 Million EUR | -100.0% |
| 2022 Q3 | -3.14 Million EUR | 57.56% |
| 2022 Q2 | -7.41 Million EUR | -100.0% |
| 2022 Q1 | -3.7 Million EUR | 25.41% |
| 2021 Q4 | -4.97 Million EUR | -100.0% |
| 2021 FY | -9.14 Million EUR | -70.84% |
| 2021 Q3 | -2.48 Million EUR | 38.57% |
| 2021 Q2 | -4.04 Million EUR | -100.0% |
| 2021 Q1 | -2.02 Million EUR | 35.41% |
| 2020 FY | -5.35 Million EUR | 19.51% |
| 2020 Q3 | -1.56 Million EUR | 27.74% |
| 2020 Q2 | -2.16 Million EUR | -100.0% |
| 2020 Q1 | -1.08 Million EUR | 0.0% |
| 2020 Q4 | -3.13 Million EUR | -100.0% |
| 2019 FY | -6.64 Million EUR | -46.22% |
| 2018 FY | -4.54 Million EUR | -17.82% |
| 2017 FY | -3.85 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -460.46% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 86.654% |
| Adocia SA | -21.16 Million EUR | 6.828% |
| Aelis Farma SA | -5.07 Million EUR | -288.283% |
| Biophytis S.A. | -17.02 Million EUR | -15.805% |
| Advicenne S.A. | -7.03 Million EUR | -180.43% |
| genOway Société anonyme | 1.56 Million EUR | 1357.803% |
| IntegraGen SA | -171.39 Thousand EUR | -11403.568% |
| Medesis Pharma S.A. | -3.95 Million EUR | -397.968% |
| Neovacs S.A. | -8.74 Million EUR | -125.506% |
| NFL Biosciences SA | -3.74 Million EUR | -426.422% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 25004.95% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -521.802% |
| Sensorion SA | -22.06 Million EUR | 10.635% |
| Theranexus Société Anonyme | -6.82 Million EUR | -188.769% |
| TME Pharma N.V. | -6.73 Million EUR | -192.711% |
| Valbiotis SA | -7.36 Million EUR | -167.603% |
| TheraVet SA | -1.57 Million EUR | -1155.295% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 3.082% |
| argenx SE | -272.91 Million EUR | 92.775% |
| BioSenic S.A. | -28.77 Million EUR | 31.486% |
| Celyad Oncology SA | -8.44 Million EUR | -133.393% |
| DBV Technologies S.A. | -67.26 Million EUR | 70.689% |
| Galapagos NV | 211.69 Million EUR | 109.314% |
| Genfit S.A. | -28.89 Million EUR | 31.761% |
| GeNeuro SA | -14.75 Million EUR | -33.611% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -28.199% |
| Innate Pharma S.A. | -7.57 Million EUR | -160.462% |
| Inventiva S.A. | -110.42 Million EUR | 82.145% |
| MedinCell S.A. | -25.03 Million EUR | 21.252% |
| Nanobiotix S.A. | -39.7 Million EUR | 50.335% |
| Onward Medical N.V. | -36.18 Million EUR | 45.505% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -488.051% |
| OSE Immunotherapeutics SA | -23 Million EUR | 14.285% |
| Oxurion NV | -18.96 Million EUR | -3.943% |
| Pharming Group N.V. | -9.75 Million EUR | -102.089% |
| Poxel S.A. | -35.09 Million EUR | 43.81% |
| GenSight Biologics S.A. | -26.22 Million EUR | 24.802% |
| Transgene SA | -22.32 Million EUR | 11.694% |
| Financière de Tubize SA | 88.15 Million EUR | 122.367% |
| UCB SA | 343 Million EUR | 105.748% |
| Valneva SE | -101.42 Million EUR | 80.561% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 30.432% |